OraSure Technologies (OSUR) reported quarterly earnings results on Wednesday, Aug-3-2016. The company said it had a profit of $0.07 Earnings per Share for the quarter. The results exceeded Wall Street expectations beating the analyst consensus estimate by $0.02. Analysts had a consensus of $0.05. The company posted revenue of $31.36 million in the period, compared to analysts expectations of $31.18 million. The company’s revenue was up 3.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.03 EPS.
Many Wall Street Analysts have commented on OraSure Technologies. OraSure Technologies was Downgraded by Raymond James to ” Mkt Perform” on Jun 13, 2016.
OraSure Technologies closed down -0.14 points or -2.06% at $6.67 with 8,04,564 shares getting traded on Tusday. Post opening the session at $6.77, the shares hit an intraday low of $6.565 and an intraday high of $6.82 and the price fluctuated in this range throughout the day.Shares ended Tusday session in Red.
OraSure Technologies Inc. (OraSure) is involved in the development manufacture marketing and sale of oral fluid diagnostic products and specimen collection devices and other diagnostic products designed to detect or diagnose critical medical conditions. These products include OraQuick In-Home HIV Test OraQuick ADVANCE OraSure HIV-1 oral specimen collection device OraQuick HCV rapid antibody test Intercept oral fluid drug testing system OraSure QuickFlu Rapid Flu A&B Test and Q.E.D. Saliva Alcohol test. The Company also manufactures and sells a range of cryosurgical products. Through its wholly owned subsidiary DNA Genotek Inc. the Company provides oral fluid sample collection stabilization and preparation products for molecular diagnostic applications.